Literature DB >> 6198980

Pessimism concerning palliative bypass procedures for established malignant esophagorespiratory fistulas: a report of 18 patients.

A A Conlan, N Nicolaou, P G Delikaris, R Pool.   

Abstract

Eighteen patients with established malignant esophagorespiratory fistulas due to primary esophageal cancer were managed by substernal gastric bypass and isolation of the cancerous esophageal segment. Seven fistulas were esophagotracheal and 11 were esophagobronchial. Ten patients died in the hospital between two days and six weeks after operation. Eight patients left the hospital, surviving an average of 3 1/2 months, but 2 patients lived 5 and 7 months, respectively. Unrelenting respiratory infection and clinical inanition caused 7 hospital deaths in patients reestablished on oral alimentation with their fistulas disconnected. Anastomotic leaks occurred in 5 patients; three of these leaks closed. In the other 2 patients, cervicomediastinal sepsis and bilateral pneumonia with respiratory failure caused death. One patient died of anoxic cardiac arrest 48 hours postoperatively. Fifteen of the 18 patients resumed oral alimentation, but the overall results of palliative surgical therapy achieved in this series were not observably worthwhile for the majority.

Entities:  

Mesh:

Year:  1984        PMID: 6198980     DOI: 10.1016/s0003-4975(10)60295-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Treatment of a ruptured anastomotic esophageal stricture following bougienage with a Dacron-covered nitinol stent.

Authors:  W Heindel; A Gossmann; R Fischbach; O Michel; K Lackner
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Nov-Dec       Impact factor: 2.740

2.  Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA).

Authors:  Moon Ki Choi; Yeon Hee Park; Jung Yong Hong; Hee Chul Park; Yong Chan Ahn; Kwanmien Kim; Yong-Mok Shim; Won Ki Kang; Keunchil Park; Young-Hyuck Im
Journal:  Med Oncol       Date:  2009-11-19       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.